Benitec Biopharma Inc.

For the period ended Sep 30, 2026. Filed Nov 13, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 13, 2026

BNTC$9.04-0.6%Stored close · as of Nov 13, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Cash Flows

Checking your notes…

(in thousands)

	For the Three Months Ended September 30,
	2026	2025
Cash flows from operating activities:
Net loss	$(12,925)	$(8,965)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	17	13
Amortization of right-of-use assets	108	105
Stock-based compensation expense	5,508	5,180
Changes in operating assets and liabilities:
Trade and other receivables	5	30
Prepaid and other assets	(173)	156
Trade and other payables	3,661	125
Accrued employee benefits	56	37
Other long-term liabilities	239	—
Lease liabilities	(119)	(32)
Net cash used in operating activities	(3,623)	(3,351)
Cash flows from investing activities:
Net cash used in investing activities	—	—
Cash flows from financing activities:
Proceeds from exercise of pre-funded warrants, Series 2 warrants and common warrants	—	—
Net cash provided by financing activities	—	—
Effects of exchange rate changes on cash, cash equivalents, and restricted cash	19	86
Net increase in cash, cash equivalents, and restricted cash	(3,604)	(3,265)
Cash, cash equivalents, and restricted cash
Beginning of period	180,086	97,857
End of period	$176,482	$94,592
Supplemental cash flow information:
Non-cash investing:
Exercise of options to shares of common stock for receivables	$34	$—

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.